Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sigmaroc Plc | LSE:SRC | London | Ordinary Share | GB00BYX5K988 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.80 | -0.86% | 92.50 | 92.60 | 92.70 | 94.00 | 92.10 | 94.00 | 2,434,136 | 16:35:01 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investment Advice | 580.29M | 13.53M | 0.0195 | 47.49 | 647.32M |
17 November 2006, London, UK: Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY), announces that all resolutions at today's Annual General Meeting were passed. Proxy votes relating to the resolutions set out in the AGM Notice can be viewed at www.antisoma.com Enquiries: Raymond Spencer, Chief Financial Officer +44 (0)20 8799 8200 Antisoma plc Background on Antisoma Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information about Antisoma. - ---END OF MESSAGE--- Copyright � Hugin ASA 2006. All rights reserved.
1 Year Sigmaroc Chart |
1 Month Sigmaroc Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
